HMBD-501 is a next generation ADC composed of a best-in-class anti-HER3 Fab with picomolar 
affinity and an engineered Fc domain to alleviate FcγR signaling. An exatecan payload is site-
specifically conjugated to the antibody with a hydrophilic linker that enhances ADC stability and 
reduces macropinocytosis—abrogates off-target FcγR mediated uptake and enhances ADC 
profile and reduces systemic toxicity.

HMBD-501 shows superior tumor growth inhibition in lung and breast cancer 
models.

HMBD-501 is well tolerated in mice and rats, with no statistically significant 
change from baseline observed for body weight, biochemistry or hematology.